{"entity":{"id":"nct07296341","kind":"trial","name":"HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Adebrelimab and Gemcitabine in pancreatic ductal adenocarcinoma, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.","summary":"HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT07296341 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 60 participants planned, started 2026-01-08 and due to reach its primary completion in 2027-10. Interventions recorded: HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine and HRS-4642;nab-paclitaxel; gemcitabine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07296341","url":"https://clinicaltrials.gov/study/NCT07296341"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["adebrelimab","gemcitabine"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07296341","phase":"1/2","setting":"A Phase IB/II Study To Evaluate the Safety, Tolerability, and Preliminary Efficacy of HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","participation":[{"nct":"NCT07296341","source":"https://clinicaltrials.gov/study/NCT07296341","fetchedAt":"2026-10-07T16:55:38.126Z","studySha256":"a0ef13b37ac5d7908a34feb54386d448dabccf466b1d281ba6cf0f476db061cb","overallStatus":"RECRUITING","lastUpdatePosted":"2026-01-14","leadSponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":60,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-01-08","startedType":"actual","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07296341/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}